Sales & Marketing Evolving HCP access requires a new connected approach to bui... Specialty medicines – treatments designed for very small patient populations with complex and rare conditions – are on the rise.
R&D In conversation with Chris Moore: Declining HCP access During the 10th anniversary of the Veeva R&D and Quality Summit, held in Madrid in June, web editor Nicole Raleigh sat down with Chris Moore, president of Europe for Veeva Systems, to d
Market Access Shifting HCP access calls for new field tactics globally Even before COVID-19 pushed access to an all-time low, access had been declining
News Grifols board backs IPO for US business Spanish plasma medicine specialist Grifols is planning to sell a minority stake in its US business, via an IPO, to help pay down its debt.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.